CRMD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.860

Open

6.620

VWAP

6.71

Vol

1.82M

Mkt Cap

531.22M

Low

6.550

Amount

12.22M

EV/EBITDA(TTM)

3.21

Total Shares

79.05M

EV

528.50M

EV/OCF(TTM)

3.02

P/S(TTM)

1.73

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Show More

Events Timeline

(ET)

2026-03-06

17:20:00

CorMedix Maintains FY27 DefenCath Sales Outlook of $150M-$170M

2026-03-05 (ET)

2026-03-05

07:40:00

CorMedix Q4 Revenue $128.615M Beats Expectations

2026-02-02 (ET)

2026-02-02

08:40:00

CorMedix Approves $75 Million Share Repurchase Program

2026-01-08 (ET)

2026-01-08

16:30:00

Major Averages Mixed as Oil Prices Surge Nearly 4%

2026-01-08

12:00:00

Major Averages Mixed Near Noon as Investors Reassess 2026 Optimism

2026-01-08

08:20:00

CorMedix Appoints Mike Seckler as EVP & Chief Commercial Officer

News

NASDAQ.COM

03-06NASDAQ.COM

CorMedix Reports 2025 Financial Results and Guidance

seekingalpha

03-05seekingalpha

CorMedix Q4 2025 Earnings Call Insights

seekingalpha

03-05seekingalpha

CorMedix Q4 2025 Earnings Misses Expectations

stocktwits

03-05stocktwits

CorMedix Reports Q4 Revenue Surge Amid Mixed Earnings

moomoo

CORMEDIX Q4 OPERATING EXPENSES REVISED TO USD 48.182 MILLION

seekingalpha

03-05seekingalpha

CorMedix Q4 Earnings Beat Expectations, Share Buyback Plan Approved

4 Analyst Rating

Wall Street analysts forecast CRMD stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

13.67

High

15.00

Current: 0.000

Low

13.00

Averages

13.67

High

15.00

Leerink

Outperform

to

Outperform

downgrade

$15 -> $13

AI Analysis

2026-03-06

New

Reason

Leerink

Price Target

$15 -> $13

AI Analysis

2026-03-06

New

downgrade

Outperform

to

Outperform

Reason

Leerink lowered the firm's price target on CorMedix to $13 from $15 and keeps an Outperform rating on the shares.

H.C. Wainwright

Buy

downgrade

$18 -> $13

2026-01-23

Reason

H.C. Wainwright

Price Target

$18 -> $13

2026-01-23

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on CorMedix to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following the updated 2026-2027 DefenCath guidance. CorMedix has entered the next phase of the story where clinical execution now matters more than commercial execution, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for CorMedix Inc (CRMD.O) is 4.34, compared to its 5-year average forward P/E of -4.41. For a more detailed relative valuation and DCF analysis to assess CorMedix Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.41

Current PE

4.34

Overvalued PE

36.86

Undervalued PE

-45.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

1.68

Current EV/EBITDA

3.78

Overvalued EV/EBITDA

8.57

Undervalued EV/EBITDA

-5.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4125.13

Current PS

1.95

Overvalued PS

18561.31

Undervalued PS

-10311.05

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 17 candidates

Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 5 - 40Is Index Component: GSPC, RUT, DJI, NDXOne Week Predict Return: 0.0% - 100.0%News Driver: Positive

Ticker

Name

Market Cap$

Marathon Petroleum Corp

64.06B

McDonald's Corp

232.62B

Chevron Corp

378.92B

Cardinal Health Inc

50.83B

Riley Exploration Permian Inc

698.78M

CorMedix Inc

498.02M

find a stock that could rise 1000%

Intellectia · 20 candidates

Market Cap: 300.00M - 5.00BQuarter Revenue Yoy Growth: >= 40.0%Beta: HighRiskRevenue 5yr Cagr: >= 25List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

TG Therapeutics Inc

4.84B

MARA Holdings Inc

3.76B

Lucid Group Inc

3.58B

CorMedix Inc

628.74M

Real Brokerage Inc

766.72M

Procept Biorobotics Corp

1.61B

best stock under 20 dollars to invest in

Intellectia · 19 candidates

Market Cap: 500.00M - 10.00BPrice: <= $20.00Net Margin: >= 20.00Weekly Average Turnover: >= 1,000,000Pe Ttm: <= 15Annual Eps Yoy Growth: >= 40.0%

Ticker

Name

Market Cap$

Centerra Gold Inc

3.55B

Fortuna Mining Corp

3.30B

Qfin Holdings Inc

2.12B

Dynex Capital Inc

2.11B

Slide Insurance Holdings Inc

2.04B

SharpLink Gaming Inc

1.96B

List stocks with high sales growth rates.

Intellectia · 665 candidates

Quarter Revenue Yoy Growth: >= 10.0%Revenue 5yr Cagr: >= 10

Ticker

Name

Market Cap$

Vision Marine Technologies Inc

4.48M

BridgeBio Pharma Inc

15.06B

Eos Energy Enterprises Inc

5.68B

Bonk Inc

25.65M

Nuscale Power Corp

5.98B

Dominari Holdings Inc

65.65M

Whales Holding CRMD

Deep Track Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is CorMedix Inc (CRMD) stock price today?

The current price of CRMD is 6.72 USD — it has increased 2.44

What is CorMedix Inc (CRMD)'s business?

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

What is the price predicton of CRMD Stock?

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is13.67 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CorMedix Inc (CRMD)'s revenue for the last quarter?

CorMedix Inc revenue for the last quarter amounts to 104.28M USD, increased 810.22

What is CorMedix Inc (CRMD)'s earnings per share (EPS) for the last quarter?

CorMedix Inc. EPS for the last quarter amounts to 1.26 USD, decreased -2620.00

How many employees does CorMedix Inc (CRMD). have?

CorMedix Inc (CRMD) has 191 emplpoyees as of March 11 2026.

What is CorMedix Inc (CRMD) market cap?

Today CRMD has the market capitalization of 531.22M USD.